• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    5/16/24 8:06:53 AM ET
    $DBVT
    $DYNT
    $EYEN
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $DBVT alert in real time by email

    Gainers

    • Lucy Scientific Discovery (NASDAQ:LSDI) stock moved upwards by 123.5% to $1.14 during Thursday's pre-market session. The market value of their outstanding shares is at $2.0 million.
    • SINTX Techs (NASDAQ:SINT) stock moved upwards by 19.67% to $0.15. The market value of their outstanding shares is at $18.7 million. As per the press release, Q1 earnings came out 3 days ago.
    • Dynatronics (NASDAQ:DYNT) stock increased by 16.7% to $0.51. The market value of their outstanding shares is at $2.7 million.
    • Ontrak (NASDAQ:OTRK) shares moved upwards by 15.99% to $0.31. The company's market cap stands at $14.8 million. The company's, Q1 earnings came out 2 days ago.
    • NovaBay Pharmaceuticals (AMEX:NBY) shares moved upwards by 15.5% to $0.12. The market value of their outstanding shares is at $4.5 million.
    • DBV Technologies (NASDAQ:DBVT) stock increased by 13.36% to $0.65. The company's market cap stands at $125.6 million.

    Losers

    • Eyenovia (NASDAQ:EYEN) shares declined by 13.6% to $0.92 during Thursday's pre-market session. The company's market cap stands at $46.6 million. The company's, Q1 earnings came out yesterday.
    • NexImmune (NASDAQ:NEXI) shares decreased by 12.27% to $3.04. The company's market cap stands at $4.1 million.
    • Monte Rosa Therapeutics (NASDAQ:GLUE) stock declined by 10.9% to $4.66. The market value of their outstanding shares is at $235.3 million.
    • Pieris Pharmaceuticals (NASDAQ:PIRS) stock decreased by 10.12% to $10.22. The company's market cap stands at $12.6 million.
    • Strata Skin Sciences (NASDAQ:SSKN) stock decreased by 9.29% to $0.38. The market value of their outstanding shares is at $13.3 million. As per the press release, Q1 earnings came out yesterday.
    • SCWorx (NASDAQ:WORX) shares declined by 8.55% to $2.14. The company's market cap stands at $2.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $DBVT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DBVT
    $DYNT
    $EYEN
    $GLUE

    CompanyDatePrice TargetRatingAnalyst
    DBV Technologies S.A.
    $DBVT
    12/15/2025$42.00Overweight
    Cantor Fitzgerald
    DBV Technologies S.A.
    $DBVT
    12/3/2025$35.00Buy
    Guggenheim
    DBV Technologies S.A.
    $DBVT
    5/29/2025$7.25Sell
    Goldman
    Monte Rosa Therapeutics Inc.
    $GLUE
    12/19/2024$14.00 → $11.00Overweight → Equal Weight
    Wells Fargo
    Eyenovia Inc.
    $EYEN
    11/18/2024$12.00 → $2.00Buy → Neutral
    H.C. Wainwright
    Monte Rosa Therapeutics Inc.
    $GLUE
    2/15/2024$11.00Outperform
    Wedbush
    Ontrak Inc.
    $OTRK
    12/5/2023$4.00Buy
    ROTH MKM
    DBV Technologies S.A.
    $DBVT
    1/4/2023Hold → Buy
    Societe Generale
    More analyst ratings

    $DBVT
    $DYNT
    $EYEN
    $GLUE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Anderson Mark Lewis bought $9,060 worth of shares (3,000 units at $3.02), increasing direct ownership by 20% to 18,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/19/26 9:00:04 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Chief Investment Officer Honigblum Gregg R. bought $34,896 worth of shares (8,200 units at $4.26), increasing direct ownership by 4% to 201,067 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    12/9/25 8:00:05 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $DBVT
    $DYNT
    $EYEN
    $GLUE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026

    Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345  Date  Total number of shares Total number of voting rights02/28/2026 278,352,082  Total gross of voting rights: 278,352,082  Total net* of voting rights: 278,236,200  * Net total = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version

    3/3/26 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting

    Châtillon, France, February 28, 2026 DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting Approximately 83% of children treated with the VIASKIN® Peanut Patch increased their eliciting dose at month 12, compared to approximately 48% in the placebo groupApproximately 60% of children treated with the VIASKIN® Peanut Patch increased their eliciting dose by at least two doses at month 12, compared to 23% in the placebo group24% of children on placebo decreased their eliciting dose between the baseline and month 12 double-blind, placebo-controlled food challenge, compared to only 6.4% of children treated with the VIASKIN® Peanut Pat

    2/28/26 2:25:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)

    In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, including 2 patients with RECIST partial responses and 3 with stable disease, all showing reduction in size of target lesions Across all 15 evaluable patients, the overall RECIST disease control rate was 67%, and 10 of 15 patients showed tumor size reductions of target lesions Combination of MRT-2359 and enzalutamide was generally well-tolerated with primarily Grade 1-2 adverse events (AEs); no treatment discontinuations due to AEs Company plans to initiate a new, signal-confirming Phase 2 stud

    2/24/26 7:00:00 AM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    $DYNT
    $EYEN
    $GLUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Principal Accounting Officer Dunn Edmund exercised 25,700 shares at a strike of $13.41 and sold $464,886 worth of shares (25,700 units at $18.09) (SEC Form 4)

    4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)

    3/2/26 5:02:46 PM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Chief Medical Officer Janku Filip sold $179,161 worth of shares (9,189 units at $19.50), decreasing direct ownership by 12% to 65,837 units (SEC Form 4)

    4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)

    2/24/26 4:05:11 PM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    $DYNT
    $EYEN
    $GLUE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for MYDCOMBI issued to EYENOVIA INC.

    Submission status for EYENOVIA INC.'s drug MYDCOMBI (ORIG-1) with active ingredient TROPICAMIDE AND PHENYLEPHRINE HYDROCHLORIDE has changed to 'Approval' on 05/05/2023. Application Category: NDA, Application Number: 215352, Application Classification: Type 5 - New Formulation or New Manufacturer

    5/8/23 1:05:04 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DBVT
    $DYNT
    $EYEN
    $GLUE
    SEC Filings

    View All

    SEC Form DEFA14A filed by NovaBay Pharmaceuticals Inc.

    DEFA14A - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)

    3/2/26 5:21:00 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 15-12G filed by Strata Skin Sciences Inc.

    15-12G - STRATA Skin Sciences, Inc. (0001051514) (Filer)

    3/2/26 4:30:54 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by DBV Technologies S.A.

    8-K - DBV Technologies S.A. (0001613780) (Filer)

    3/2/26 7:54:26 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    $DYNT
    $EYEN
    $GLUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on DBV Technologies with a new price target

    Cantor Fitzgerald initiated coverage of DBV Technologies with a rating of Overweight and set a new price target of $42.00

    12/15/25 9:59:53 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on DBV Technologies with a new price target

    Guggenheim initiated coverage of DBV Technologies with a rating of Buy and set a new price target of $35.00

    12/3/25 8:16:35 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Goldman resumed coverage on DBV Technologies with a new price target

    Goldman resumed coverage of DBV Technologies with a rating of Sell and set a new price target of $7.25

    5/29/25 8:17:33 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    $DYNT
    $EYEN
    $GLUE
    Financials

    Live finance-specific insights

    View All

    Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects

    In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated rapid and durable reductions in systemic inflammation  After four weeks of MRT-8102 treatment, C-reactive protein (CRP) levels were reduced by 85%, and 94% of study participants achieved CRP values below 2 mg/L, a threshold associated with reduced cardiovascular disease (CVD) risk Single ascending dose (SAD) and multiple ascending dose (MAD) cohorts demonstrated deep and sustained NEK7 degradation at doses from 5 mg to 400 mg Favorable safety profile observed with mild to moderate adve

    1/7/26 7:00:00 AM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results

    BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Wednesday, January 7, at 8:00 a.m. ET. The webcast presentation will highlight interim clinical results from the ongoing Phase 1 study of the NEK7-directed MGD MRT-8102, including interim data from the ongoing Part 3 CRP proof-of-concept cohort in subjects with elevated cardiovascular disease risk. A webcast of the presentation will be accessible via the "Events & Presentations" section of Monte Rosa's website at ir.montero

    1/6/26 4:05:00 PM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

    Châtillon, France, December 16, 2025 DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years VITESSE met its primary endpoint: the lower bound of the 95% confidence interval (CI) of the difference between treatment arms was 24.5%, exceeding the prespecified threshold of 15% 46.6% of children treated with the VIASKIN® Peanut patch met response criteria at 12 months, compared to 14.8% of children in the placebo arm Safety results were consistent with the safety profile observed in the VIASKIN Peanut clinical program to dateBLA submission in 4-7-year-olds on track for the first half of 2026Achievement

    12/16/25 4:05:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    $DYNT
    $EYEN
    $GLUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Pieris Pharmaceuticals Inc.

    SC 13G/A - PALVELLA THERAPEUTICS, INC. (0001583648) (Subject)

    12/17/24 5:42:35 PM ET
    $PIRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Eyenovia Inc.

    SC 13D/A - EYENOVIA, INC. (0001682639) (Subject)

    12/4/24 4:12:20 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DBVT
    $DYNT
    $EYEN
    $GLUE
    Leadership Updates

    Live Leadership Updates

    View All

    SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

    Appointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX Technologies, Inc., effective March 16, 2026. Mr. Elmore most recently served as Core Business Director at Invibio, a division of Victrex plc. With more than 15 years of experience in advanced biomaterials and medical dev

    2/18/26 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

    Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr. Trapp will report directly to Daniel Tasse, Chief Executive Officer, as a member of the executive team and will lead all aspects of global commercial strategy and execution for the Viaskin® Peanut patch. DBV expects to submit a Biologics License Application (BLA) submission for children 4-7 years-old living with peanut allergy in the first half of 2026, followed by an anticipated BLA su

    11/3/25 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors

    Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (TRQX:DBVp), (the "Company" or "DBV"), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee, to its Board of Directors (the "Board"), effective October 30, 2025. Dr. Lee is appointed in replacement of Daniel Soland, subject to the ratification by the Company's shareholders at the next annual meeting of shareholders. Dr. Lee will also serve as a member of the Compensation Committee of the Board. With this addition, the Company's Board comprises ten directors. "We are pleased

    10/30/25 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care